GELSOMINO, FRANCESCO
GELSOMINO, FRANCESCO
DIPARTIMENTO DI MEDICINA SPECIALISTICA, DIAGNOSTICA E SPERIMENTALE (attivo dal 28/10/2011 al 31/12/2022)
Collaboratori
An open-label, randomized phase III study of early switch maintenance vs delayed second-line nivolumab in advanced stage squamous non-small cell lung cancer (NSCLC) patients after standard first-line platinum-based chemotherapy-EDEN trial GOIRC 04-2016
2025 Gelsomino, Francesco; Boni, Luca; Tiseo, Marcello; Ricciardi, Serena; Rocco, Danilo; Cortinovis, Diego L; Proietto, Manuela; Cogoni, Alessio; Pasello, Giulia; Camerini, Andrea; Sperandi, Francesca; Colantonio, Ida; Metro, Giulio; Mazzoni, Francesca; Baldini, Editta; Veccia, Antonello; Bennicelli, Elisa; Cecilia Bettini, Anna; Tognetto, Michele; Ardizzoni, Andrea
Lung adenocarcinomas with mucinous histology: clinical, genomic, and immune microenvironment characterization and outcomes to immunotherapy-based treatments and KRASG12C inhibitors
2025 Di Federico, A; Hong, L; Elkrief, A; Thummalapalli, R; Cooper, A J; Ricciuti, B; Digumarthy, S; Alessi, J V; Gogia, P; Pecci, F; Makarem, M; Gandhi, M M; Garbo, E; Saini, A; De Giglio, A; Favorito, V; Scalera, S; Cipriani, L; Marinelli, D; Haradon, D; Nguyen, T; Haradon, J; Voligny, E; Vaz, V; Gelsomino, F; Sperandi, F; Melotti, B; Ladanyi, M; Zhang, J; Gibbons, D L; Heymach, J V; Nishino, M; Lindsay, J; Rodig, S J; Pfaff, K; Sholl, L M; Wang, X; Johnson, B E; Jänne, P A; Rekhtman, N; Maugeri-Saccà, M; Heist, R S; Ardizzoni, A; Awad, M M; Arbour, K C; Schoenfeld, A J; Vokes, N I; Luo, J
PD-L1 and IFN-γ modulate Non-Small Cell Lung Cancer (NSCLC) cell plasticity associated to immune checkpoint inhibitor (ICI)-mediated hyperprogressive disease (HPD)
2025 Angelicola, Stefania; Giunchi, Francesca; Ruzzi, Francesca; Frascino, Mariateresa; Pitzalis, Mary; Scalambra, Laura; Semprini, Maria Sofia; Pittino, Olga Maria; Cappello, Chiara; Siracusa, Irene; Chillico, Ilaria Candida; Di Noia, Martina; Turato, Cristian; De Siervi, Silvia; Lescai, Francesco; Ciavattini, Teresa; Lopatriello, Giulia; Bertoli, Luca; De Jonge, Hugo; Iamele, Luisa; Altimari, Annalisa; Gruppioni, Elisa; Ardizzoni, Andrea; Rossato, Marzia; Gelsomino, Francesco; Lollini, Pier-Luigi; Palladini, Arianna
STK11 mutations correlate with poor prognosis for advanced NSCLC treated with first-line immunotherapy or chemo-immunotherapy according to KRAS, TP53, KEAP1, and SMARCA4 status
2025 De Giglio, Andrea; De Biase, Dario; Favorito, Valentina; Maloberti, Thais; Di Federico, Alessandro; Zacchini, Federico; Venturi, Giulia; Parisi, Claudia; Gustavo Dall'Olio, Filippo; Ricciotti, Ilaria; Gagliano, Ambrogio; Melotti, Barbara; Sperandi, Francesca; Altimari, Annalisa; Gruppioni, Elisa; Tallini, Giovanni; Gelsomino, Francesco; Montanaro, Lorenzo; Ardizzoni, Andrea
Activity of osimeRTInib in non-small-cell lung Cancer with UNcommon epidermal growth factor receptor mutations: retrospective Observational multicenter study (ARTICUNO)
2024 Pizzutilo, E G; Agostara, A G; Oresti, S; Signorelli, D; Stabile, S; Lauricella, C; Motta, V; Amatu, A; Ruggieri, L; Brambilla, M; Occhipinti, M; Proto, C; Giusti, R; Filetti, M; Genova, C; Barletta, G; Gelsomino, F; Bennati, C; Siringo, M; Di Fazio, G R; Russano, M; Montrone, M; Gariazzo, E; Roca, E; Bordi, P; Delmonte, A; Scimone, A; Belluomini, L; Mazzoni, F; Carta, A; Pelizzari, G; Viscardi, G; Morgillo, F; Gelibter, A; Gori, S; Berardi, R; Cortinovis, D; Ardizzoni, A; Veronese, S M; Sartore-Bianchi, A; Giannetta, L G; Cerea, G; Siena, S
Peripheral nervous system adverse events associated with immune checkpoint inhibitors
2023 Rossi S.; Gelsomino F.; Rinaldi R.; Muccioli L.; Comito F.; Di Federico A.; De Giglio A.; Lamberti G.; Andrini E.; Mollica V.; D'Angelo R.; Baccari F.; Zenesini C.; Madia P.; Raschi E.; Cortelli P.; Ardizzoni A.; Guarino M.
Phase II study of capecitabine-based concomitant chemoradiation followed by durvalumab as a neoadjuvant strategy in locally advanced rectal cancer: the PANDORA trial
2023 Grassi, E; Zingaretti, C; Petracci, E; Corbelli, J; Papiani, G; Banchelli, I; Valli, I; Frassineti, G L; Passardi, A; Di Bartolomeo, M; Pietrantonio, F; Gelsomino, F; Carandina, I; Banzi, M; Martella, L; Bonetti, A V; Boccaccino, A; Molinari, C; Marisi, G; Ugolini, G; Nanni, O; Tamberi, S
EGFR-RAD51 gene fusion NSCLC responsiveness to different generation EGFR-TKIs: two cases and review of the literature
2022 Di Federico, Alessandro; Filetti, Marco; Palladini, Arianna; Giusti, Raffaele; Piras, Marta; De Giglio, Andrea; Ardizzoni, Andrea; Gelsomino, Francesco
Immune checkpoint inhibitors in lung tumors with rare histologies and other thoracic malignancies
2022 Andrini E.; Di Federico A.; Sisi M.; Rosellini M.; Palladini A.; Lamberti G.; De Giglio A.; Gelsomino F.
Next-generation technologies in predictive molecular pathology of lung cancers
2022 de Biase, Dario; Maloberti, Thais; De Leo, Antonio; Sanza, Viviana; Visani, Michela; Gruppioni, Elisa; Altimari, Annalisa; Grillini, Alessia; Gelsomino, Francesco; Ferrari, Marco; Ardizzoni, Andrea; Tallini, Giovanni
Psychiatric Adverse Reactions to Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer: Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System
2022 Sisi, Monia; Fusaroli, Michele; De Giglio, Andrea; Facchinetti, Francesco; Ardizzoni, Andrea; Raschi, Emanuel; Gelsomino, Francesco
IFN-γ and CD38 in Hyperprogressive Cancer Development
2021 Angelicola, Stefania; Ruzzi, Francesca; Landuzzi, Lorena; Scalambra, Laura; Gelsomino, Francesco; Ardizzoni, Andrea; Nanni, Patrizia; Lollini, Pier-Luigi; Palladini, Arianna
Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience
2020 Vitale G.; Lamberti G.; Comito F.; Di Nunno V.; Massari F.; Morelli M.C.; Ardizzoni A.; Gelsomino F.
Atezolizumab in a CoHort of pretreated, advanced, non-small cell lung cancer patients with rare HistologiCal SubtypEs (CHANCE trial)
2020 Gelsomino F.; Lamberti G.; Tiseo M.; Rocco D.; Pasello G.; Cecere F.L.; Chella A.; Grilli G.; Mandruzzato M.; Tognetto M.; Garassino M.C.; Macerelli M.; Novello S.; Roila F.; Colantonio I.; Grossi F.; Fiorentino M.; Ardizzoni A.
Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma
2020 Lamberti G.; Andrini E.; Sisi M.; Rizzo A.; Parisi C.; Di Federico A.; Gelsomino F.; Ardizzoni A.
Evolution of cystic airspaces lung lesions on immune checkpoint inhibition in non-small cell lung cancer
2020 Parisi C.; Lamberti G.; Zompatori M.; Gelsomino F.; Salvagni S.; Sperandi F.; Ardizzoni A.
Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance
2020 Raschi E.; Gatti M.; Gelsomino F.; Ardizzoni A.; Poluzzi E.; De Ponti F.
New disappearance of complicated atheromatous plaques on rechallenge with PD-1/PD-L1 axis blockade in non-small cell lung cancer patient: follow up of an unexpected event
2020 Lamberti G.; Gelsomino F.; Brocchi S.; Poerio A.; Melotti B.; Sperandi F.; Gargiulo M.; Borghi C.; Fiorentino M.; Ardizzoni A.
Overcoming Primary Resistance to PD-1 Inhibitor With Anti–PD-L1 Agent in Squamous-Cell NSCLC: Case Report
2020 Gelsomino, F.; Di Federico, A.; Filippini, D. M.; Dall'Olio, F. G.; Lamberti, G.; Sperandi, F.; Balacchi, C.; Brocchi, S.; Ardizzoni, A.
Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL)
2020 Gelsomino F.; Tiseo M.; Barbieri F.; Riccardi F.; Cavanna L.; Frassoldati A.; Delmonte A.; Longo L.; Dazzi C.; Cinieri S.; Colantonio I.; Sperandi F.; Lamberti G.; Brocchi S.; Tofani L.; Boni L.; Ardizzoni A.
| Titolo | Autore(i) | Anno | Periodico | Editore | Tipo | File |
|---|---|---|---|---|---|---|
| An open-label, randomized phase III study of early switch maintenance vs delayed second-line nivolumab in advanced stage squamous non-small cell lung cancer (NSCLC) patients after standard first-line platinum-based chemotherapy-EDEN trial GOIRC 04-2016 | Gelsomino, Francesco; Boni, Luca; Tiseo, Marcello; Ricciardi, Serena; Rocco, Danilo; Cortinovis, ...Diego L; Proietto, Manuela; Cogoni, Alessio; Pasello, Giulia; Camerini, Andrea; Sperandi, Francesca; Colantonio, Ida; Metro, Giulio; Mazzoni, Francesca; Baldini, Editta; Veccia, Antonello; Bennicelli, Elisa; Cecilia Bettini, Anna; Tognetto, Michele; Ardizzoni, Andrea | 2025-01-01 | LUNG CANCER | - | 1.01 Articolo in rivista | Gelsomino_2025.pdf; mmc1.pdf |
| Lung adenocarcinomas with mucinous histology: clinical, genomic, and immune microenvironment characterization and outcomes to immunotherapy-based treatments and KRASG12C inhibitors | Di Federico, A; Hong, L; Elkrief, A; Thummalapalli, R; Cooper, A J; Ricciuti, B; Digumarthy, S; A...lessi, J V; Gogia, P; Pecci, F; Makarem, M; Gandhi, M M; Garbo, E; Saini, A; De Giglio, A; Favorito, V; Scalera, S; Cipriani, L; Marinelli, D; Haradon, D; Nguyen, T; Haradon, J; Voligny, E; Vaz, V; Gelsomino, F; Sperandi, F; Melotti, B; Ladanyi, M; Zhang, J; Gibbons, D L; Heymach, J V; Nishino, M; Lindsay, J; Rodig, S J; Pfaff, K; Sholl, L M; Wang, X; Johnson, B E; Jänne, P A; Rekhtman, N; Maugeri-Saccà, M; Heist, R S; Ardizzoni, A; Awad, M M; Arbour, K C; Schoenfeld, A J; Vokes, N I; Luo, J | 2025-01-01 | ANNALS OF ONCOLOGY | - | 1.01 Articolo in rivista | - |
| PD-L1 and IFN-γ modulate Non-Small Cell Lung Cancer (NSCLC) cell plasticity associated to immune checkpoint inhibitor (ICI)-mediated hyperprogressive disease (HPD) | Angelicola, Stefania; Giunchi, Francesca; Ruzzi, Francesca; Frascino, Mariateresa; Pitzalis, Mary...; Scalambra, Laura; Semprini, Maria Sofia; Pittino, Olga Maria; Cappello, Chiara; Siracusa, Irene; Chillico, Ilaria Candida; Di Noia, Martina; Turato, Cristian; De Siervi, Silvia; Lescai, Francesco; Ciavattini, Teresa; Lopatriello, Giulia; Bertoli, Luca; De Jonge, Hugo; Iamele, Luisa; Altimari, Annalisa; Gruppioni, Elisa; Ardizzoni, Andrea; Rossato, Marzia; Gelsomino, Francesco; Lollini, Pier-Luigi; Palladini, Arianna | 2025-01-01 | JOURNAL OF TRANSLATIONAL MEDICINE | - | 1.01 Articolo in rivista | Hyperprog NSCLC JTranslMed.pdf; 12967_2024_6023_MOESM3_ESM.zip |
| STK11 mutations correlate with poor prognosis for advanced NSCLC treated with first-line immunotherapy or chemo-immunotherapy according to KRAS, TP53, KEAP1, and SMARCA4 status | De Giglio, Andrea; De Biase, Dario; Favorito, Valentina; Maloberti, Thais; Di Federico, Alessandr...o; Zacchini, Federico; Venturi, Giulia; Parisi, Claudia; Gustavo Dall'Olio, Filippo; Ricciotti, Ilaria; Gagliano, Ambrogio; Melotti, Barbara; Sperandi, Francesca; Altimari, Annalisa; Gruppioni, Elisa; Tallini, Giovanni; Gelsomino, Francesco; Montanaro, Lorenzo; Ardizzoni, Andrea | 2025-01-01 | LUNG CANCER | - | 1.01 Articolo in rivista | STK11 mutations LUNG CANCER2025.pdf |
| Activity of osimeRTInib in non-small-cell lung Cancer with UNcommon epidermal growth factor receptor mutations: retrospective Observational multicenter study (ARTICUNO) | Pizzutilo, E G; Agostara, A G; Oresti, S; Signorelli, D; Stabile, S; Lauricella, C; Motta, V; Ama...tu, A; Ruggieri, L; Brambilla, M; Occhipinti, M; Proto, C; Giusti, R; Filetti, M; Genova, C; Barletta, G; Gelsomino, F; Bennati, C; Siringo, M; Di Fazio, G R; Russano, M; Montrone, M; Gariazzo, E; Roca, E; Bordi, P; Delmonte, A; Scimone, A; Belluomini, L; Mazzoni, F; Carta, A; Pelizzari, G; Viscardi, G; Morgillo, F; Gelibter, A; Gori, S; Berardi, R; Cortinovis, D; Ardizzoni, A; Veronese, S M; Sartore-Bianchi, A; Giannetta, L G; Cerea, G; Siena, S | 2024-01-01 | ESMO OPEN | - | 1.01 Articolo in rivista | 1-s2.0-S2059702924013619-main.pdf; 1-s2.0-S2059702924013619-mmc1.docx |
| Peripheral nervous system adverse events associated with immune checkpoint inhibitors | Rossi S.; Gelsomino F.; Rinaldi R.; Muccioli L.; Comito F.; Di Federico A.; De Giglio A.; Lambert...i G.; Andrini E.; Mollica V.; D'Angelo R.; Baccari F.; Zenesini C.; Madia P.; Raschi E.; Cortelli P.; Ardizzoni A.; Guarino M. | 2023-01-01 | JOURNAL OF NEUROLOGY | - | 1.01 Articolo in rivista | Rossi_JN_2023.pdf |
| Phase II study of capecitabine-based concomitant chemoradiation followed by durvalumab as a neoadjuvant strategy in locally advanced rectal cancer: the PANDORA trial | Grassi, E; Zingaretti, C; Petracci, E; Corbelli, J; Papiani, G; Banchelli, I; Valli, I; Frassinet...i, G L; Passardi, A; Di Bartolomeo, M; Pietrantonio, F; Gelsomino, F; Carandina, I; Banzi, M; Martella, L; Bonetti, A V; Boccaccino, A; Molinari, C; Marisi, G; Ugolini, G; Nanni, O; Tamberi, S | 2023-01-01 | ESMO OPEN | - | 1.01 Articolo in rivista | main.pdf |
| EGFR-RAD51 gene fusion NSCLC responsiveness to different generation EGFR-TKIs: two cases and review of the literature | Di Federico, Alessandro; Filetti, Marco; Palladini, Arianna; Giusti, Raffaele; Piras, Marta; De G...iglio, Andrea; Ardizzoni, Andrea; Gelsomino, Francesco | 2022-01-01 | TRANSLATIONAL LUNG CANCER RESEARCH | - | 1.01 Articolo in rivista | Di Federico_EGFR-RAD51_Trans Lung Cancer Res_22.pdf |
| Immune checkpoint inhibitors in lung tumors with rare histologies and other thoracic malignancies | Andrini E.; Di Federico A.; Sisi M.; Rosellini M.; Palladini A.; Lamberti G.; De Giglio A.; Gelso...mino F. | 2022-01-01 | IMMUNOTHERAPY | - | 1.01 Articolo in rivista | - |
| Next-generation technologies in predictive molecular pathology of lung cancers | de Biase, Dario; Maloberti, Thais; De Leo, Antonio; Sanza, Viviana; Visani, Michela; Gruppioni, E...lisa; Altimari, Annalisa; Grillini, Alessia; Gelsomino, Francesco; Ferrari, Marco; Ardizzoni, Andrea; Tallini, Giovanni | 2022-01-01 | Journal of Xiangya Medicine | - | 1.01 Articolo in rivista | 8323-PB5-2020-R3.pdf |
| Psychiatric Adverse Reactions to Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer: Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System | Sisi, Monia; Fusaroli, Michele; De Giglio, Andrea; Facchinetti, Francesco; Ardizzoni, Andrea; Ras...chi, Emanuel; Gelsomino, Francesco | 2022-01-01 | TARGETED ONCOLOGY | - | 1.01 Articolo in rivista | Sisi2022_Article_PsychiatricAdverseReactionsToA.pdf; 11523_2021_865_MOESM1_ESM.pdf |
| IFN-γ and CD38 in Hyperprogressive Cancer Development | Angelicola, Stefania; Ruzzi, Francesca; Landuzzi, Lorena; Scalambra, Laura; Gelsomino, Francesco;... Ardizzoni, Andrea; Nanni, Patrizia; Lollini, Pier-Luigi; Palladini, Arianna | 2021-01-01 | CANCERS | - | 1.01 Articolo in rivista | CD38 cancers-13-00309-v2.pdf |
| Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience | Vitale G.; Lamberti G.; Comito F.; Di Nunno V.; Massari F.; Morelli M.C.; Ardizzoni A.; Gelsomino F. | 2020-01-01 | EXPERT OPINION ON BIOLOGICAL THERAPY | - | 1.01 Articolo in rivista | - |
| Atezolizumab in a CoHort of pretreated, advanced, non-small cell lung cancer patients with rare HistologiCal SubtypEs (CHANCE trial) | Gelsomino F.; Lamberti G.; Tiseo M.; Rocco D.; Pasello G.; Cecere F.L.; Chella A.; Grilli G.; Man...druzzato M.; Tognetto M.; Garassino M.C.; Macerelli M.; Novello S.; Roila F.; Colantonio I.; Grossi F.; Fiorentino M.; Ardizzoni A. | 2020-01-01 | THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | - | 1.01 Articolo in rivista | Gelsomino_CHANCE_TAMO'20.pdf |
| Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma | Lamberti G.; Andrini E.; Sisi M.; Rizzo A.; Parisi C.; Di Federico A.; Gelsomino F.; Ardizzoni A. | 2020-01-01 | CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | - | 1.01 Articolo in rivista | - |
| Evolution of cystic airspaces lung lesions on immune checkpoint inhibition in non-small cell lung cancer | Parisi C.; Lamberti G.; Zompatori M.; Gelsomino F.; Salvagni S.; Sperandi F.; Ardizzoni A. | 2020-01-01 | JOURNAL FOR IMMUNOTHERAPY OF CANCER | - | 1.01 Articolo in rivista | Parisi_Cystic airspaces_JIC'20.pdf |
| Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance | Raschi E.; Gatti M.; Gelsomino F.; Ardizzoni A.; Poluzzi E.; De Ponti F. | 2020-01-01 | TARGETED ONCOLOGY | - | 1.01 Articolo in rivista | ICI_Targeted_Oncology_2020.pdf; 11523_2020_738_MOESM1_ESM.pdf |
| New disappearance of complicated atheromatous plaques on rechallenge with PD-1/PD-L1 axis blockade in non-small cell lung cancer patient: follow up of an unexpected event | Lamberti G.; Gelsomino F.; Brocchi S.; Poerio A.; Melotti B.; Sperandi F.; Gargiulo M.; Borghi C....; Fiorentino M.; Ardizzoni A. | 2020-01-01 | THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | - | 1.01 Articolo in rivista | Lamberti_atheromatous plaque_TAMO'20.pdf |
| Overcoming Primary Resistance to PD-1 Inhibitor With Anti–PD-L1 Agent in Squamous-Cell NSCLC: Case Report | Gelsomino, F.; Di Federico, A.; Filippini, D. M.; Dall'Olio, F. G.; Lamberti, G.; Sperandi, F.; B...alacchi, C.; Brocchi, S.; Ardizzoni, A. | 2020-01-01 | CLINICAL LUNG CANCER | - | 1.01 Articolo in rivista | - |
| Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL) | Gelsomino F.; Tiseo M.; Barbieri F.; Riccardi F.; Cavanna L.; Frassoldati A.; Delmonte A.; Longo ...L.; Dazzi C.; Cinieri S.; Colantonio I.; Sperandi F.; Lamberti G.; Brocchi S.; Tofani L.; Boni L.; Ardizzoni A. | 2020-01-01 | BRITISH JOURNAL OF CANCER | - | 1.01 Articolo in rivista | s41416-020-0845-3.pdf; 41416_2020_845_MOESM1_ESM.doc |